.Attributes Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint requires inclusion of people with MASLD and also dimension of liver outcomes in cardio-- kidney-- metabolic tests, when data propose mechanistically plausible perks and also clinical security-- as well as describes factors to consider for trial concept as well as regulative approval.